O	0	3	The	The	DT	B-NP
O	4	16	differential	differential	JJ	I-NP
O	17	27	regulation	regulation	NN	I-NP
O	28	30	of	of	IN	B-PP
O	31	36	human	human	JJ	B-NP
O	37	47	telomerase	telomerase	NN	I-NP
O	48	55	reverse	reverse	JJ	I-NP
O	56	69	transcriptase	transcriptase	NN	I-NP
O	70	73	and	and	CC	O
O	74	82	vascular	vascular	JJ	B-NP
O	83	94	endothelial	endothelial	JJ	I-NP
O	95	101	growth	growth	NN	I-NP
O	102	108	factor	factor	NN	I-NP
O	109	112	may	may	MD	B-VP
O	113	123	contribute	contribute	VB	I-VP
O	124	126	to	to	TO	B-PP
O	127	130	the	the	DT	B-NP
O	131	141	clinically	clinically	RB	I-NP
O	142	146	more	more	RBR	I-NP
O	147	157	aggressive	aggressive	JJ	I-NP
O	158	166	behavior	behavior	NN	I-NP
O	167	169	of	of	IN	B-PP
B-Cancer	170	173	p63	p63	NN	B-NP
I-Cancer	173	174	-	-	HYPH	B-NP
I-Cancer	174	182	positive	positive	JJ	I-NP
I-Cancer	183	189	breast	breast	NN	I-NP
I-Cancer	190	200	carcinomas	carcinoma	NNS	I-NP
O	200	201	.	.	.	O

O	202	205	p63	p63	NN	B-NP
O	205	206	,	,	,	O
O	207	208	a	a	DT	B-NP
O	209	212	p53	p53	NN	I-NP
O	213	222	homologue	homologue	NN	I-NP
O	222	223	,	,	,	O
O	224	226	is	be	VBZ	B-VP
O	227	228	a	a	DT	B-NP
B-Cell	229	242	myoepithelial	myoepithelial	JJ	I-NP
I-Cell	243	247	cell	cell	NN	I-NP
O	248	254	marker	marker	NN	I-NP
O	255	257	in	in	IN	B-PP
O	258	261	the	the	DT	B-NP
O	262	268	normal	normal	JJ	I-NP
B-Organ	269	276	mammary	mammary	JJ	I-NP
I-Organ	277	282	gland	gland	NN	I-NP
O	283	286	but	but	CC	I-NP
B-Cell	287	290	p63	p63	NN	I-NP
I-Cell	290	291	-	-	HYPH	B-NP
I-Cell	291	299	positive	positive	JJ	I-NP
I-Cell	300	310	neoplastic	neoplastic	JJ	I-NP
I-Cell	311	316	cells	cell	NNS	I-NP
O	317	320	may	may	MD	B-VP
O	321	323	be	be	VB	I-VP
O	324	329	found	find	VBN	I-VP
O	330	332	in	in	IN	B-PP
O	333	335	up	up	IN	B-NP
O	336	338	to	to	TO	I-NP
O	339	341	11	11	CD	I-NP
O	341	342	%	%	NN	I-NP
O	343	345	of	of	IN	B-PP
B-Cancer	346	354	invasive	invasive	JJ	B-NP
I-Cancer	355	361	breast	breast	NN	I-NP
I-Cancer	362	372	carcinomas	carcinoma	NNS	I-NP
O	372	373	.	.	.	O

O	374	378	This	This	DT	B-NP
O	379	384	study	study	NN	I-NP
O	385	389	aims	aim	VBZ	B-VP
O	390	392	to	to	TO	I-VP
O	393	399	verify	verify	VB	I-VP
O	400	403	the	the	DT	B-NP
O	404	416	relationship	relationship	NN	I-NP
O	417	424	between	between	IN	B-PP
O	425	428	p63	p63	NN	B-NP
O	429	439	expression	expression	NN	I-NP
O	440	443	and	and	CC	O
O	444	451	several	several	JJ	B-NP
O	452	471	clinicopathological	clinicopathological	JJ	I-NP
O	472	480	features	feature	NNS	I-NP
O	481	484	and	and	CC	O
B-Cancer	485	490	tumor	tumor	NN	B-NP
O	491	498	markers	marker	NNS	I-NP
O	499	501	of	of	IN	B-PP
O	502	510	clinical	clinical	JJ	B-NP
O	511	523	significance	significance	NN	I-NP
O	524	526	in	in	IN	B-PP
B-Cancer	527	533	breast	breast	NN	B-NP
I-Cancer	534	543	pathology	pathology	NN	I-NP
O	544	553	including	include	VBG	B-PP
O	554	557	key	key	JJ	B-NP
O	558	568	regulators	regulator	NNS	I-NP
O	569	571	of	of	IN	B-PP
O	572	575	the	the	DT	B-NP
B-Cell	576	580	cell	cell	NN	I-NP
O	581	586	cycle	cycle	NN	I-NP
O	586	587	,	,	,	O
O	588	597	oncogenes	oncogene	NNS	B-NP
O	597	598	,	,	,	O
O	599	608	apoptosis	apoptosis	NN	B-NP
O	608	609	-	-	HYPH	B-NP
O	609	616	related	relate	VBN	I-NP
O	617	625	proteins	protein	NNS	I-NP
O	625	626	,	,	,	O
O	627	645	metalloproteinases	metalloproteinas	NNS	B-NP
O	646	649	and	and	CC	O
O	650	655	their	their	PRP$	B-NP
O	656	666	inhibitors	inhibitor	NNS	I-NP
O	666	667	.	.	.	O

O	668	688	Immunohistochemistry	Immunohistochemistry	NN	B-NP
O	689	693	with	with	IN	B-PP
O	694	696	27	27	CD	B-NP
O	697	704	primary	primary	JJ	I-NP
O	705	715	antibodies	antibody	NNS	I-NP
O	716	719	was	be	VBD	B-VP
O	720	729	performed	perform	VBN	I-VP
O	730	732	in	in	IN	B-PP
O	733	736	100	100	CD	B-NP
O	737	745	formalin	formalin	NN	I-NP
O	745	746	-	-	HYPH	O
O	746	751	fixed	fix	VBN	B-NP
O	752	760	paraffin	paraffin	NN	I-NP
O	760	761	-	-	HYPH	B-NP
O	761	769	embedded	embed	VBN	I-NP
B-Cancer	770	777	samples	sample	NNS	I-NP
O	778	780	of	of	IN	B-PP
B-Cancer	781	789	invasive	invasive	JJ	B-NP
I-Cancer	790	796	ductal	ductal	JJ	I-NP
I-Cancer	797	807	carcinomas	carcinoma	NNS	I-NP
O	807	808	.	.	.	O

B-Cell	809	812	p63	p63	NN	B-NP
I-Cell	812	813	-	-	HYPH	I-NP
I-Cell	813	821	positive	positive	JJ	I-NP
I-Cell	822	827	cells	cell	NNS	I-NP
O	828	832	were	be	VBD	B-VP
O	833	838	found	find	VBN	I-VP
O	839	841	in	in	IN	B-PP
O	842	844	16	16	CD	B-NP
O	844	845	%	%	NN	I-NP
O	846	848	of	of	IN	B-PP
B-Cancer	849	859	carcinomas	carcinoma	NNS	B-NP
O	859	860	.	.	.	O

B-Cancer	861	864	p63	p63	NN	B-NP
I-Cancer	864	865	-	-	HYPH	I-NP
I-Cancer	865	873	positive	positive	JJ	I-NP
I-Cancer	874	884	carcinomas	carcinoma	NNS	I-NP
O	885	889	were	be	VBD	B-VP
O	890	896	poorly	poorly	RB	I-VP
O	897	911	differentiated	differentiate	VBN	I-VP
O	911	912	,	,	,	O
O	913	920	hormone	hormone	NN	B-NP
O	921	929	receptor	receptor	NN	I-NP
O	929	930	-	-	HYPH	B-NP
O	930	938	negative	negative	JJ	I-NP
B-Cancer	939	948	neoplasms	neoplasm	NNS	I-NP
O	949	953	with	with	IN	B-PP
O	954	955	a	a	DT	B-NP
O	956	960	high	high	JJ	I-NP
O	961	974	proliferation	proliferation	NN	I-NP
O	975	979	rate	rate	NN	I-NP
O	979	980	.	.	.	O

O	981	984	p63	p63	NN	B-NP
O	985	989	also	also	RB	B-ADVP
O	990	1000	correlated	correlate	VBD	B-VP
O	1001	1005	with	with	IN	B-PP
O	1006	1014	advanced	advance	VBN	B-NP
O	1015	1027	pathological	pathological	JJ	I-NP
O	1028	1033	stage	stage	NN	I-NP
O	1033	1034	,	,	,	O
B-Cancer	1035	1040	tumor	tumor	NN	B-NP
O	1041	1045	size	size	NN	I-NP
O	1045	1046	,	,	,	O
O	1047	1050	and	and	CC	O
O	1051	1054	the	the	DT	B-NP
O	1055	1065	expression	expression	NN	I-NP
O	1066	1068	of	of	IN	B-PP
O	1069	1074	human	human	JJ	B-NP
O	1075	1085	telomerase	telomerase	NN	I-NP
O	1086	1093	reverse	reverse	JJ	I-NP
O	1094	1107	transcriptase	transcriptase	NN	I-NP
O	1108	1109	(	(	(	O
O	1109	1114	hTERT	hTERT	NN	B-NP
O	1114	1115	)	)	)	O
O	1115	1116	,	,	,	O
O	1117	1123	tissue	tissue	NN	B-NP
O	1124	1133	inhibitor	inhibitor	NN	I-NP
O	1134	1136	of	of	IN	B-PP
O	1137	1143	matrix	matrix	NN	B-NP
O	1144	1161	metalloproteinase	metalloproteinase	NN	I-NP
O	1162	1163	1	1	CD	I-NP
O	1164	1165	(	(	(	O
O	1165	1170	TIMP1	TIMP1	NN	B-NP
O	1170	1171	)	)	)	O
O	1172	1175	and	and	CC	O
O	1176	1184	vascular	vascular	JJ	B-NP
O	1185	1196	endothelial	endothelial	JJ	I-NP
O	1197	1203	growth	growth	NN	I-NP
O	1204	1210	factor	factor	NN	I-NP
O	1211	1212	(	(	(	O
O	1212	1216	VEGF	VEGF	NN	B-NP
O	1216	1217	)	)	)	O
O	1217	1218	.	.	.	O

O	1219	1222	The	The	DT	B-NP
O	1223	1233	expression	expression	NN	I-NP
O	1234	1236	of	of	IN	B-PP
O	1237	1242	TIMP1	TIMP1	NN	B-NP
O	1243	1251	suggests	suggest	VBZ	B-VP
O	1252	1256	that	that	IN	B-SBAR
O	1257	1260	the	the	DT	B-NP
O	1261	1265	anti	anti	AFX	I-NP
O	1265	1266	-	-	HYPH	I-NP
O	1266	1277	proteolytic	proteolytic	JJ	I-NP
O	1278	1285	stimuli	stimulus	NNS	I-NP
O	1286	1289	may	may	MD	B-VP
O	1290	1292	be	be	VB	I-VP
O	1293	1305	preponderant	preponderant	JJ	B-ADJP
O	1306	1308	in	in	IN	B-PP
B-Cancer	1309	1312	p63	p63	NN	B-NP
I-Cancer	1312	1313	-	-	HYPH	B-NP
I-Cancer	1313	1321	positive	positive	JJ	I-NP
I-Cancer	1322	1332	carcinomas	carcinoma	NNS	I-NP
O	1332	1333	.	.	.	O

O	1334	1339	hTERT	hTERT	NN	B-NP
O	1340	1348	activity	activity	NN	I-NP
O	1349	1351	is	be	VBZ	B-VP
O	1352	1362	associated	associate	VBN	I-VP
O	1363	1367	with	with	IN	B-PP
B-Cancer	1368	1373	nodal	nodal	JJ	B-NP
I-Cancer	1374	1384	metastases	metastasis	NNS	I-NP
O	1385	1388	and	and	CC	O
B-Cell	1389	1397	cellular	cellular	JJ	B-NP
O	1398	1411	proliferation	proliferation	NN	I-NP
O	1411	1412	.	.	.	O

O	1413	1417	VEGF	VEGF	NN	B-NP
O	1418	1427	regulates	regulate	VBZ	B-VP
O	1428	1440	angiogenesis	angiogenesis	NN	B-NP
O	1440	1441	,	,	,	O
O	1442	1447	which	which	WDT	B-NP
O	1448	1450	is	be	VBZ	B-VP
O	1451	1455	also	also	RB	B-ADVP
O	1456	1457	a	a	DT	B-NP
O	1458	1469	fundamental	fundamental	JJ	I-NP
O	1470	1475	event	event	NN	I-NP
O	1476	1478	in	in	IN	B-PP
O	1479	1482	the	the	DT	B-NP
O	1483	1490	process	process	NN	I-NP
O	1491	1493	of	of	IN	B-PP
B-Cancer	1494	1499	tumor	tumor	NN	B-NP
O	1500	1506	growth	growth	NN	I-NP
O	1507	1510	and	and	CC	O
O	1511	1521	metastatic	metastatic	JJ	B-NP
O	1522	1535	dissemination	dissemination	NN	I-NP
O	1535	1536	.	.	.	O

O	1537	1541	Thus	Thus	RB	B-ADVP
O	1541	1542	,	,	,	O
O	1543	1546	the	the	DT	B-NP
O	1547	1559	differential	differential	JJ	I-NP
O	1560	1570	regulation	regulation	NN	I-NP
O	1571	1573	of	of	IN	B-PP
O	1574	1579	hTERT	hTERT	NN	B-NP
O	1580	1583	and	and	CC	I-NP
O	1584	1588	VEGF	VEGF	NN	I-NP
O	1589	1591	in	in	IN	B-PP
B-Cancer	1592	1595	p63	p63	NN	B-NP
I-Cancer	1595	1596	-	-	HYPH	B-NP
I-Cancer	1596	1604	positive	positive	JJ	I-NP
I-Cancer	1605	1611	breast	breast	NN	I-NP
I-Cancer	1612	1622	carcinomas	carcinoma	NNS	I-NP
O	1623	1626	may	may	MD	B-VP
O	1627	1637	contribute	contribute	VB	I-VP
O	1638	1640	to	to	TO	B-PP
O	1641	1644	the	the	DT	B-NP
O	1645	1655	clinically	clinically	RB	I-NP
O	1656	1660	more	more	RBR	I-NP
O	1661	1671	aggressive	aggressive	JJ	I-NP
O	1672	1680	behavior	behavior	NN	I-NP
O	1681	1683	of	of	IN	B-PP
O	1684	1689	these	these	DT	B-NP
B-Cancer	1690	1699	neoplasms	neoplasm	NNS	I-NP
O	1699	1700	.	.	.	O

